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1INTRODUCTION
Pleural infection is a clinical problem with annual incidence of up
to 80,000 cases in the western world. Mortality and morbidity is high;
20% of patients with empyema die and approximately 20% require
surgery to recover within 12 months of their infection.1 2
          Despite the advent of effective antibiotics, bacterial pneumonia still
results in significant morbidity and mortality in the population. In one
study of 1,424 patients hospitalized with community-acquired
pneumonia, patients with pleural effusions were 2.7 times more likely to
be treatment failures than were those without pleural effusions.3
In another study, the relative risk of mortality in patients with
community-acquired pneumonia was 7.0 times higher for patients with
bilateral pleural effusions and 3.4 times higher for patients with unilateral
pleural effusion of moderate or greater size as compared with other
patients with community-acquired pneumonia alone 4.
Most pleural effusions associated with pneumonia resolve without
any specific therapy directed toward the pleural fluid, but approximately
10% of patients require operative intervention. Delay in instituting proper
2therapy for these effusions is responsible for some of the morbidity
associated with parapneumonic effusions. 5
For a simple parapneumonic effusion antibiotics according to
culture and sensitivity will suffice.
In complicated parapneumonic effusion and empyema intervention
in the form of thoracentesis, tube thoracostomy, thoracoscopic
intervention, surgery will be needed accordingly.
3AIM OF THE STUDY
To  describe the bacteriology of pleural space infection and to
determine the prognostic factors implied in the outcome of pleural space
infection chiefly simple complicated and complex parapneumonic
effusion admitted from period of June 2009 to June 2011 in tertiary care
respiratory institute (Government hospital of thoracic medicine
Tambaram sanatorium) under Stanley medical college Chennai.
It was hypothesized that there could be clinical , laboratory and
biochemical prognostic factors determining the outcome of
parapneumonic effusion that if identified at the optimal period would
result in reduction in morbidity and mortality associated with
parapneumonic  effusion.  This  study  was  aimed  at  identification  of  such
determinants.
4LITERATURE REVIEW
Anatomy of the Pleura
The pleural space has two membranes, the visceral pleura covering
the lung and the parietal pleura covering the chest wall and diaphragm.
Into pleural space, normal protein and liquid enter from circulation and
are eliminated by the parietal pleural lymphatic. Pleural pressure is sub
atmospheric and ensures inflation of the lung. The mesothelium is leaky,
excess fluid migrate across into this lower-pressure, high-capacitance
space and collect as a pleural effusion.  Each pleural membrane has a
single cell layer of mesothelial cells. There shape may be flat to cuboidal
or columnar, based on the degree of stretching of the underlying
submesothelial tissue. These most numerous cell of the pleural space,
may have a variety of functions important to pleural biology7 .Mesothelial
cells can secrete the macromolecular components of the extracellular
matrix and organize them into mature matrix, phagocytose particles, and
secrete neutrophil and monocyte chemotactic factors that may be
important for inflammatory cell recruitment into the pleural spaces can
produce fibrinolytic and procoagulant factors. The mesothelial cells
5produce cytokines such as transforming growth factor-?, epidermal
growth factor (EGF), and platelet-derived growth factor, cytokines that
are important in pleural inflammation and fibrosis.
Mesothelial cells produce hyaluronan but not mucin, express
keratin microfilaments, stain negatively with epithelial-specific
antibodies (Ber-EP4, B72.3, Leu.M1, and CEA), and stain positively for
calretinin and mesothelin—all features that are important for
histochemical and immunohistochemical identification of the cells in
pleural effusions.8 9
Physiology of pleural space
Normal pleural fluid arises from the systemic pleural vessels in
both pleurae, flows across the leaky pleural membranes into the pleural
space, and exits the pleural space via the parietal pleural lymphatic.10,11
The pleural space is similar to other interstitial spaces of the body.
The evidence for this view.
1. Intrapleural pressure is lower than the interstitial pressure of either
of the pleural tissues. Pressure gradient makes a liquid movement
into but not out of the pleural space.
62. The pleural membranes are leaky to liquid and protein. Whether
tested in vitro12,13 or in situ,14 the pleura offers  little  resistance to
liquid or protein movement.
3. Various transporters and aquaporins are present in mesothelial
cells  but no role in reabsorption of effusions.15 Normal pleural
liquid has been reported to be alkaline with higher bicarbonate
than plasma, No evidence for active mesothelial role in generation
of bicarbonate gradient, which can more likely be explained by a
passive response to protein gradients (Donnan equlibrium).16
4. Pleural liquid entry is compatible with known interstitial flow
rates  as  it  is  slow.  Noninvasive  studies  of  the  equilibration  of
radiolabeled albumin have shown that, the  rate of entry pleural
liquid is approximately about 0.5 mL/hr or 12 mL/day in an adult
human and 0.01 mL/kg/hr in a sheep, .17
5. The protein concentration of normal pleural liquid is low in sheep
& humans11  impling sieving of the protein across a high-pressure
gradient. The protein concentration of sheep pleural liquid
(10 g/L) and pleural–to–plasma protein concentration ratio (0.15)
are similar to those of filtrates from high-pressure systemic
vessels. By comparison, a filtrate from low-pressure pulmonary
vessels has a higher protein concentration (45 g/L) and ratio
(lymph–to–plasma protein concentration ratio 0.69.19
76. Pleural fluid exits by bulk  flow, not by diffusion or active
transport, evident by the protein concentration of pleural effusions
remaining   constant  as  the  effusion  is  absorbed,  as  is   with  bulk
flow. Absorption by diffusion or active transport, proteins would
diffuse at a slower rate, and the protein concentration would
progressively increase. Moreover erythrocytes instilled into the
pleural space are absorbed intact and in almost the same
proportion as the liquid and protein.11 This denotes that the major
route of exit is via holes large enough to accommodate sheep
erythrocytes (6–8 mm diameter). The only possible exit is via the
parietal pleural stomata (10–12 mm diameter) into the pleural
lymphatics.11
Pathophysiology
To form an effusion, it is likely that both the entry rate of liquid
must increase and the exit rate must decrease.  If only the entry rate
increased, it would require rate more than 30 times normal to exceed the
reserve lymphatic removal capacity; if the exit rate decreased, it would
take more than a month at the normal entry rate of 12 mL/day to produce
an effusion detectable by chest radiograph. 19
Most  of  pleural  infection  exemplify  a  progressive  process  that
metamorphoses’ a ‘simple’ self  resolving parapneumonic pleural
8effusion into a ‘complicated’ multiloculated fibrinopurulent collection
associated with clinical and/or biochemical features of sepsis . 20
The development of empyema in association with pneumonia  has
been classified into three stages as:
(1) a simple exudate,
(2) a fibrinopurulent stage and
(3) a later organising stage with scar tissue (pleural peel)
formation.  20
In the early exudative stage there is fluid movement into the pleural
space due to increased capillary vascular permeability. There is also
production of proinflammatory cytokines such as interleukin 8 (IL-8) and
tumor necrosis factor alfa (TNFa).21 Mesothelial cells to facilitate fluid
entry . At first, the fluid is a free-flowing exudate characterised by a low
white cell count, an LDH level less than half that in the serum, normal pH
and glucose levels and does not contain bacterial organisms. 22-26 This
stage, when the pleural fluid is a straightforward sterile exudate, is often
called a ‘simple parapneumonic effusion’. Treatment with antibiotics at
this stage is likely to be adequate and most effusions of this type do not
require chest tube drainage. 23- 24
9If optimal treatment is not commenced, a simple parapneumonic
effusion may progress to the fibrinopurulent stage with increasing fluid
accumulation and bacterial invasion across the damaged endothelium.
Bacterial invasion accelerates the immune response, promoting further
migration of neutrophil and activation of the coagulation cascade leading
to increased procoagulant and depressed fibrinolytic activity.  27-28
The stages of a parapneumonic effusion are
(1) exudative  (capillary leak) - period of 5 to 7 days;
(2) fibrinopurulent  or bacterial invasion and fibrin formation
stage, -  after   7 days up to 2 weeks; and
(3) the organizational or empyema stage, which generally occurs
within 2 to 4 weeks of onset of the pleural effusion.
An anaerobic infection, prolonged pneumonia history, failure to
respond to antibiotic therapy, virulence of the underlying bacterial
pathogen, and hypoalbuminemia also suggest the presence of a
complicated parapneumonic effusion.29-30
Bacteriology of community-acquired and hospital-acquired pleural
infection 2
10
Common organisms
Community-acquired Streptococcus spp. (52%)
? S milleri
? S pneumoniae
? S intermedius
? Staphylococcus aureus (11%)
      Gram-negative aerobes (9%)
? Enterobacteriaceae
? Escherichia coli
       Anaerobes (20%)
? Fusobacterium spp.
? Bacteroides spp.
? Peptostreptococcus spp.
? Mixed
      Hospital-acquired Staphylococci
? Methicillin-resistant S aureus (MRSA) (25%)
? S aureus (10%)
11
     Gram-negative aerobes (17%)
o E coli
o Pseudomonas aeruginosa
o Klebsiella spp.
o Anaerobes (8%)
Transudate vs Exudate
Light and colleagues31  have devised a diagnostic  rule for   pleural
effusion  as  an  exudate.  An  exudative  effusion  if  any  one  of  :  (1)  a  PF
lactate dehydrogenase (LDH) level  >0.67, ie, the upper limit of normal
for the laboratory serum LDH value; (2) a PF/serum protein ratio > 0.5;
and (3) a PF/serum LDH ratio >0.6. The use of a three-test combination
with “and/or” rule maximizes diagnostic sensitivity for detecting
exudative pleural effusions but lowers specificity.
In a receiver operating characteristic analysis of 200 consecutive
patients with pleural effusions, a PF LDH of 163 IU/L (serum upper
limits of normal, 200; ratio _ 0.82) was the best cutoff point for an
exudates (area under the curve, 0.89), followed by PF/serum total protein
ratio of 0.5 (area under the curve, 0.86).
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APPROACH TO PATIENTS WITH PLEURAL
EFFUSION
Dullness to percussion, decreased breath sounds, egophony at the
upper level of the effusion and decreased tactile fremitus are the physical
findings of a pleural effusion. Signs can include asymmetrical chest
expansion or even bulging of the intercostal spaces with large effusions.
The most useful physical findings were dullness to percussion and
decreased tactile fremitus.33
Abnormal chest radiograph should arise suspicion. Increased
densities attributed to parenchymal infiltrates when they can represent
pleural fluid. The posterior costophrenic sulcus is the most dependent part
of the thoracic cavity where free pleural fluid gravitates to when the
patient is upright. Therefore, if the posterior costophrenic angle is blunted
or if the posterior part of the diaphragm is not visible on the lateral chest
radiograph bilateral decubitus chest radiographs or an ultrasonic
examination of the pleural space should be obtained to ascertain whether
free pleural fluid is present. If the distance between the inside of the
thoracic cavity and the outside of the lung is less than 10 mm, the pleural
13
effusion is not likely to be clinically significant and in any case  will be
difficult to obtain by thoracentesis. If the distance is greater than 10 mm,
an effort should be made to determine the cause of the pleural effusion.
Differential Diagnosis of Pleural Effusion
Pleural effusion accompanies many different diseases.  Most
common causes of pleural effusions is in table.  Almost all transudative
pleural effusions are due to CHF and cirrhosis.  Pneumonia, malignant
pleural disease, pulmonary embolism, and gastrointestinal disease
account for at least 90% of all exudative pleural effusions.
TABLE  -- Differential Diagnoses of Pleural Effusions 34
TRANSUDATIVE PLEURAL EFFUSIONS
Congestive heart failure
Pericardial disease
Hepatic hydrothorax
Nephrotic syndrome
Peritoneal dialysis
Urinothorax
Myxedema
Fontan procedure
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Central venous occlusion
Subarachnoid-pleural fistula
Veno-occlusive disease
Bone marrow transplantation
Iatrogenic
EXUDATIVE PLEURAL EFFUSIONS
       Neoplastic diseases
Metastatic disease
Mesothelioma
Primary effusion lymphoma
Pyothorax-associated
lymphoma
Infectious diseases
Pyogenic bacterial infections
Tuberculosis
Actinomycosis and nocardiosis
Fungal infections
Viral infections
Parasitic infections
Pulmonary embolism
15
Gastrointestinal disease
Esophageal perforation
Pancreatic disease
Intra-abdominal abscesses
Diaphragmatic hernia
Postabdominal surgery
Collagen vascular diseases
Rheumatoid pleuritis
Systemic lupus erythematosus
Drug-induced lupus
Immunoblastic lymphadenopathy
Sjogren's syndrome
Churg-Strauss syndrome
Wegener's granulomatosis
Postcardiac injury syndrome
Post–coronary artery bypass surgery
Asbestos exposure
Sarcoidosis
Uremia
Meigs’ syndrome
Ovarian hyperstimulation syndrome
16
Yellow nail syndrome
Drug-induced pleural disease
Nitrofurantoin
Dantrolene
Methysergide
Bromocriptine
Procarbazine
Amiodarone
Dasatinib
Radiation therapy
Electric burns
Iatrogenic injury
Hemothorax
Chylothorax
Separation of Exudates from Transudates
On nearly every patient with free pleural fluid that measures more
than 10 mm on the decubitus radiograph a diagnostic thoracentesis should
be performed. If CHF is obvious, postpone the thoracentesis until the
heart failure is treated. If the patient is febrile or has pleuritic chest pain
17
or  if  the  effusions  are  not  of  comparable  size  on  both  sides,  a
thoracentesis should be performed without delay.
Thoracentesis when performed by an experienced operator is a safe
procedure.
It can be safely performed in patients with coagulopathies and
thrombocytopenia and in patients on positive mechanical ventilation
because of the small-bore needle required.35
Exudative pleural effusions meet at least one of the following
criteria, whereas transudative pleural effusions meet none32: (1) pleural
fluid protein–to–serum protein greater than 0.50; (2) pleural fluid LDH–
to–serum LDH greater than 0.60; and (3) pleural fluid LDH greater than
two thirds of the upper normal limit for serum. If none of these criteria is
met, the patient has a transudative pleural effusion, and the pleural
surfaces can be ignored while the CHF, cirrhosis, or nephrosis is treated.
In the rare cases in which malignancy has been associated with a
transudate, extrapleural effects of the tumor or other causes such as
concurrent CHF are the most likely cause as evidenced by the rarity of a
positive cytology in those effusions.19 36
18
The previously discussed criteria may misidentify a transudative
effusion as an exudative effusion in as many as 25% of cases. If a patient
appears to have a transudative effusion clinically, additional tests can be
assessed to verify its transudative etiology. If the difference between the
protein concentration of serum and the pleura exceeds 3.1 gm/dL, the
patient in all probability has a transudative effusion.37 If pleural
concentrations of N-terminal brain natriuretic peptide (NT-BNP) are
elevated (>1300 pg/mL), the patient likely has a transudate from a cardiac
cause.38
Differentiating Exudative Pleural Effusions
Pneumonia, malignancy, and pulmonary embolism account for the
great majority of all exudative pleural effusions. Undiagnosed exudative
pleural effusions, the appearance of the fluid should be noted, pleural
fluid protein and LDH levels (if not already measured), glucose level,
differential cell count, and microbiologic and cytologic studies should be
obtained.39
In  selected  patients,  other  tests  on  the  pleural  fluid,  such  as  pH,
amylase level, antinuclear antibody (ANA) level, rheumatoid factor level,
adenosine deaminase (ADA), lipid analysis, and so forth, may be of
value.
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Appearance of Pleural Fluid
The gross appearance and odor of the pleural fluid should be noted.
If pleural fluid smells putrid, the patient has a bacterial infection
(probably anaerobic). If smells like urine, patient has a urinothorax. If the
pleural fluid is bloody, a pleural fluid hematocrit should be obtained. If it
is  greater  than  50%  that  of  the  peripheral  blood,  the  patient  has  a
hemothorax and inserting chest tubes the physician should give strong
consideration. If the pleural fluid hematocrit is less than 1%, the blood in
the pleural fluid has no clinical significance. If the pleural fluid
hematocrit is between 1% and 50%, the patient most likely has malignant
pleural disease, a pulmonary embolus, or a traumatically induced pleural
effusion.40
The supernatant of the pleural fluid should be examined if the
pleural fluid is turbid, milky, or bloody. If turbidity clears with
centrifugation,  the  turbidity  is  due  to  cells  or  debris  in  the  pleural  fluid.
The patient probably has a chylothorax or a pseudochylothorax if the
turbidity  persists  after  centrifugation.  They  can  be  differentiated  by  the
patient's history, examination of the sediment for cholesterol crystals, and
lipid analysis of the supernatant. The disease process is acute,  no
thickened  pleural  surfaces,   no  cholesterol  crystals  present,  and  the
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pleural fluid triglyceride level is usually above 110 mg/dL (1.24 mmol/L
) with chylothorax)., The disease process is usually chronic, the pleural
surfaces are usually thickened, there may be cholesterol crystals, and the
pleural fluid triglyceride level is usually not elevated with
pseudochylothorax.
Pleural Fluid Protein
If the protein level is above 5.0 g/dL, the likelihood of the
diagnosis of tuberculous pleurisy is increased, the patient probably has a
urinothorax,  an  effusion  secondary  to  peritoneal  dialysis,  a  leak  of  CSF
into the pleural space, or an effusion secondary to the misplacement of a
central intravascular line iff the pleural fluid protein level is very low
(<0.5 g/dL).
Pleural Fluid Lactate Dehydrogenase
LDH concentration should be measured during diagnostic
thoracentesis  because the level of LDH in the pleural fluid reflects the
degree of inflammation in the pleural space. LDH concentration increases
or decrease with serial thoracentesis, is directly proportional the degree of
inflammation in the pleural space.41
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Pleural Fluid Glucose
A thickened, infiltrated pleura leading to an impaired diffusion of
glucose into the pleural space plus increased metabolic activity leading to
increased glucose utilization within the pleural space can result in a low
glucose concentration. In all undiagnosed exudative pleural effusions  the
demonstration of a reduced pleural fluid glucose level (<60 mg/dL,
3.33 mmol/L) points to possibilities of parapneumonic effusion,
malignant effusion, tuberculous effusion, rheumatoid effusion,
hemothorax, paragonimiasis, or the Churg-Strauss syndrome.41 Tube
thoracostomy should be considered if a patient with a parapneumonic
effusion has a pleural fluid glucose level below 40 mg/dL (2.22 mmol/L).
Rheumatoid pleural effusions have a pleural fluid glucose level below
30 mg/dL (1.66 mmol/L).42 Patients with pleural effusion secondary to
systemic lupus erythematosus (SLE) will have a pleural fluid glucose
level above 80 mg/dL (4.44 mmol/L).43 Patients with malignant pleural
disease and a low pleural fluid glucose level usually have a positive
pleural fluid cytology.44
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Pleural Fluid White Cell Count and Differential
The cell count has been reported to be 1700 cells/mm3.45 In
effusions, the cell count has limited diagnostic value. A pleural fluid
white blood cell count of 1000/mm3 roughly separates transudative from
exudative pleural effusion.
A pleural fluid white blood cell count above 10,000/mm3 is most
common with empyemas and parapneumonic effusions, but is also seen
with collagen vascular diseases, pancreatitis, pulmonary embolism,
malignancy and tuberculosis.40
The differential cell count on the pleural fluid is much more useful.
Macrophages (75%) followed by lymphocytes (23%) is the normal
pleural space content.45 For  the  pleural  fluid  differential  cell  count,  the
cells should be partitioned into the following categories:
polymorphonuclear leukocytes, eosinophils, small lymphocytes,
mesothelial cells, and other mononuclear cells. Pleural effusions due to an
acute disease process such as pneumonia, pulmonary embolization,
pancreatitis, intra-abdominal abscess, or early tuberculosis contain
predominantly polymorphonuclear leukocytes. Pleural effusions due to a
chronic disease process contain predominantly mononuclear cells.
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Pleural fluid eosinophilia (?10% eosinophils by differential count)
is  most  commonly  due  to  air  or  blood  in  the  pleural  space.  The  pleural
liquid IL-5 levels correlates with the number and percentage of
eosinophils in the pleural space.46 Occasionally, no pleural fluid
eosinophils are found in the initial thoracentesis, but many eosinophils
are  seen  in  a  subsequent  thoracentesis  most  likely  due  to  entry  of  air  or
blood caused by the initial thoracentesis.47 With traumatic hemothorax,
pleural fluid eosinophilia does not occur until the second week. The
eosinophilia appears to be due to production of IL-5 by CD4+ T  cells
within the pleural space.48 At times, the pleural fluid eosinophilia
associated with a hemothorax can lead to eosinophilia in the peripheral
blood.49 The bloody pleural effusion complicating pulmonary embolism
frequently contains many eosinophils.50 With pneumothorax, pleural
eosinophilia appears within 3 days of the pneumothorax and reaches a
peak after 6 days.51
If the etiology of the eosinophilia is not evident, several unusual
diagnoses should be considered. Eosinophilic  cell count is seen with
benign asbestos pleural effusions.47 Patients with pleural effusions
secondary to drug reactions (nitrofurantoin or dantrolene) typically have
pleural fluid eosinophilia.41 Typically eosinophilic with low glucose, low
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pH, and high LDH level is the pleural fluid of patients with pleural
paragonimiasis.52 The  Churg-Strauss  syndrome is  the  only  other  disease
that produces this constellation of pleural fluid findings.53
Mesothelial cells line the pleural cavities. It is unusual to find
mesothelial cells in effusions due to tuberculosis. However, the absence
of mesothelial cells is also common with other conditions in which the
pleura becomes coated with fibrin, such as a complicated parapneumonic
effusion.
Small lymphocytes, when accounting for more than 50% of the
white blood cells in an exudative pleural effusion, indicate that the patient
probably has a malignant or a tuberculous pleural effusion.40 54 Because
these two diseases can be diagnosed with needle biopsy of the pleura, the
presence of pleural fluid lymphocytosis should alert the physician to
consider needle biopsy of the pleura for diagnosis. Because most
lymphocytic effusions contain a predominance of T cells (CD4+) whether
the diagnosis is malignancy or tuberculosis and hence separation of
pleural lymphocytes into T and B lymphocytes has not been useful
diagnostically.55 A diagnosis of chronic lymphocytic leukemia or
lymphoma is suspected. When, the pleural lymphocytes are
predominantly of B-cell origin.56
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Pleural Fluid Cytology
 In up to 60% of the effusions caused by pleural malignancy the
first pleural fluid cytologic study is positive for malignant cells.40 90% of
effusions due to pleural malignancy have positive cytopathology if three
separate specimens are analysed. Less than 25% of patients with
Hodgkin's disease have positive cytology58 whereas most patients with
adenocarcinomas have positive cytology.57 hence frequency of positive
pleural fluid cytologic tests is dependent on the tumor type. During
thoracoscopy, pleural lavage has been found to increase the diagnostic
yield, perhaps by harvesting more fresh cells for analysis.60 The
percentage of positive diagnoses is obviously dependent on the skill of
the cytologist. Immunohistochemical stains of malignant cells are used to
confirm a diagnosis and to specify tumor type, with many new markers
recently available.8 59
Other Diagnostic Tests for Malignancy
Abnormal numbers of specific chromosomes (aneuploidy) can be
confirmed by fluorescent in situ hybridization (FISH) with chromosome-
specific probes, thereby confirming that abnormal cells are indeed
malignant.61 DNA methylation is an early findings of malignancy  can be
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detected by methylation-specific polymerase chain reaction (PCR),62 and
gene expression patterns can help distinguish mesothelioma and
adenocarcinoma.63 EGF-receptor mutations can predict response to EGF-
receptor tyrosine kinase inhibitors. Conversely, biomarkers have
generally been disappointing due to nonspecificity.
Culture and Bacteriologic Stains
Pleural fluid from patients with undiagnosed exudative pleural
effusions should be cultured for bacteria (both aerobically and
anerobically), mycobacteria, and fungi. Gram's stain should also be
obtained. In the case of a probable complicated parapneumonic effusion
with an initial negative Gram's stain, the sediment of the pleural fluid
should be stained because the bacteria will be precipitated in the sediment
along with the white blood cells and the debris.
Amplification and sequencing of bacterial 16S ribosomal RNA has
identified bacteria in pleural empyema, showing in one study that the
bacteriology of pleural infections differed from that of pneumonia64
27
Other Diagnostic Tests for Pleural Fluid
Pleural Fluid pH and PCO2
(1) Complicated parapneumonic effusion, (2) hemothorax (3)
rheumatoid pleuritis, (4) tuberculous pleuritis, (5) urinothorax (6)
esophageal rupture, (7) systemic acidosis, (8) paragonimiasis, (9) lupus
pleuritis, or (10) malignant pleural disease are the pleural fluid pH can be
reduced to less than 7.2041. The decreased pleural fluid pH appears to
result from lactic acid and carbon dioxide accumulation in the pleural
fluid.65 Whether  chest  tubes  should  be  inserted  in  patients  with
parapneumonic effusions is determined by the pleural fluid pH .66
Blood gas machine is ideal for the pH measurement; a pH meter or
indicator paper is not useful for accurate measure.67 Pleural  fluid  pH,
altered by residual air or lidocaine in the syringe.68
Pleural Fluid Amylase
Esophageal perforation, pancreatic disease, or malignant disease
are associated with pleural fluid amylase. The pleural fluid amylase
concentration is elevated within 2 hours of esophageal rupture, the origin
of the amylase is the salivary glands.70,71 In  effusions  due  to
pancreaticopleural fistulas, the amylase concentration is extremely high
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(>4000 IU/mL), reflective of the concentrations in pancreatic secretions.72
In approximately 10% of malignant effusions, the pleural fluid amylase
level is mildly elevated. The site of the primary tumor in such patients is
usually not the pancreas.73 Malignancy can be differentiated from
pancreatic disease with amylase isoenzymes because the amylase with
malignant effusions is primarily of the salivary type.74
29
CLASSIFICATION
Class 1  Non significant
pleural effusion
<10 mm thick on decubitus x-ray.
No thoracentesis
>10 mm thick
Glucose >40 mg/dL, pH >7.2
LDH <3 Ã— upper limit normal for serum
Gram's stain and culture negative
Class 2  Typical
parapneumonic pleural
effusion
Antibiotics alone
7.0 <pH <7.20 and or
LDH >3 Ã— upper limit normal and glucose
>40 mg/dL
Gram's stain and culture negative
Class 3 Borderline
complicated pleural effusion
Antibiotics plus serial thoracentesis
pH <7.0 or glucose <40 mg/dL or
Gram's stain or culture positive
Not loculated not frank pus
Class 4 Simple complicated
pleural effusion
Tube thoracostomy plus antibiotics
pH <7.0 and/or glucose <40 mg/dL or
Gram's stain or culture positive
Multiloculated
Class 5 Complex complicated
pleural effusion
Tube thoracostomy plus fibrinolytics (rarely
require thoracoscopy or decortication)
Frank pus present
Single locule or free flowing
Class 6 Simple empyema
Tube thoracostomy Â± decortications
Frank pus present
Multiple locules
Tube thoracostomy ± fibrinolytics
Class 7 Complex empyema
Often require thoracoscopy or decortication
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Classification of the American College of Chest Physicians
ACCP   classification  of  parapneumonic  effusions  on  the  basis  of
the anatomical characteristics of the fluid (A), the bacteriology of the
pleural fluid (B) and the chemistries (C) of the pleural fluid 75.
The anatomy (A) of the pleural effusion is based on the size of the
effusion, whether it is free flowing and whether the parietal pleural is
thickened.
A0 effusions - Small effusions (<10 mm in thickness on the
decubitus radiographs, ultrasound examination, or CT scans) & free
flowing.
A1 effusions -  > 10 mm in thickness but  occupy less than 50% of
the hemithorax, are free flowing, no parietal pleural thickening.
A2 effusions occupy more than 50% of the hemithorax or are
loculated and/or are associated with thickening of the parietal pleura.
The bacteriology (B) of the effusion is based on whether smears or
cultures are positive.
Bx effusions  -   culture  and  Gram's  stain  results  are  unknown,
because the effusion was small and a thoracentesis was not done.
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B0 effusions - negative Gram's stains and cultures of the pleural
fluid.
B1 effusions-  Gram's stain or culture are positive, but  the pleural
fluid is not pus.
B2 effusions -pleural fluid is pus.
The chemistry (C) of the effusion is based on the pH of the pleural fluid.
Cx effusions - pleural fluid pH is unknown ( thoracentesis was not
done).
C0 effusions - pleural fluid pH greater than 7.20.
C1 effusions- pleural fluid pH less than 7.20.
For accurate pleural fluid pH, the pleural fluid must be measured
with a blood gas machine 74.
On the basis of the A, B, and C classification, the effusion is
categorized.
Category  1  effusion-  Small  (<10  mm   on  decubitus,  CT  scan  or
ultrasound)
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Free-flowing.
Effusion is small, no thoracentesis
                               Bacteriology and chemistry - unknown.
Risk of a poor outcome very low.
Category 2 effusion - Small to moderate in size (>10 mm & <1/2 of
hemithorax)
Free flowing.
Gram's  stain  and  culture  of  the  pleural  fluid  are
negative
Pleural fluid pH > 7.20.
The risk of a poor outcome effusion is low.
Category 3 effusion  one of the  criteria
(a) effusion > 1/2 the hemithorax, is loculated, or with a
thickened parietal pleura;
(b) Gram's stain or culture - positive; or
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(c) pleural fluid pH < 7.20 or
(d) pleural fluid glucose < 60     mg/dL.
Risk of a poor outcome - moderate.
Category 4 effusion - pleural fluid that is pus.
The risk of a poor outcome - High
Overall Treatment Plan
Treatment plan for parapneumonic effusions and empyema, are
? Diagnostic thoracentesis,
? Therapeutic thoracentesis,
? Tube thoracostomy,
? Tube thoracostomy with thrombolytics,
? Thoracoscopy, and
? Thoracotomy with decortication.
One of these treatments will be needed If the patient has any of the
poor prognostic factors, It is essential not to continue any of the
treatment that is not working for more than a day or so.78 79
34
The effectiveness of a given treatment is evaluated by the clinical
status of the patient together with the amount and the characteristics of
the pleural fluid. Success denotes that the patient appears to be
responding, and amount of pleural fluid is not large, the characteristics of
the fluid are improving.
More invasive procedures are not indicated for pleural thickening
or loculation alone. Chest CT scans are very useful in evaluating the
adequacy of drainage of the pleural space.
Diagnostic versus Therapeutic Thoracentesis
A  thoracentesis should be performed to determine if the patient
has  any  of  the  prognostic  factors.  The  risks  of  a  diagnostic  and  a
therapeutic thoracentesis are comparable, and a therapeutic thoracentesis
might prevent the need for further procedures, therefore a therapeutic
thoracentesis is recommended.78 After thoracentesis pleural fluid recurs,
Poor prognostic findings in the initial pleural fluid indicate the need for
more drainage—either an additional therapeutic thoracentesis or a tube
thoracostomy. The absence of poor prognostic findings in a patient who is
improving clinically indicates that additional drainage is not necessary.
Three therapeutic thoracenteses are all that is recommended.78
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If the pleural fluid is loculated, tube thoracostomy should be
performed if any of the other poor prognostic factors  are present. To
insert a small pigtail catheter is an alternative to therapeutic thoracentesis.
Chest Tubes
Tube thoracostomy should be not be delayed, because a
complicated parapneumonic effusion can progress from free-flowing
pleural fluid to loculated pleural fluid within hours. Mortality can be
attributed to a delay in obtaining adequate pleural drainage.76 The chest
tube should be positioned in the most dependent part of the effusion. On
the  optimal  size  of  the  chest  tube  for  drainage  ,there  is  no  agreement.77
Large (26–36 French) chest tubes were recommended in the past because
of  obstruction  by the thick fluid. Smaller tubes under image or
ultrasound guidance can suffice. The chest tube should be left in place
until the volume of the pleural drainage per 24 hours is less than 50 mL
and until the draining fluid becomes clear yellow. Closed-tube drainage
of a complicated parapneumonic effusion is associated with improvement
in the clinical and radiologic status of the patient within 24 to 48 hours is
termed Successful. Either if the pleural drainage is unsatisfactory or the
patient is receiving the wrong antibiotic  there will be no significant
improvement after this period. Then the culture results should be
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reviewed and the adequacy of the pleural drainage should be assessed by
imaging or ultrasound. Another chest tube should be inserted if the
pleural space is inadequately drained, a fibrinolytic agent or saline can be
injected intrapleurally or surgery can be performed. Poor positioning of
the tube, loculated pleural fluid, obstruction of the chest tube or
inadequate expansion of the underlying lung due to coating of the visceral
pleura leads to inadequate drainage.
Intrapleural Thrombolytic Agents
Drainage of complicated parapneumonic effusions as a result of
pleural loculations by fibrin membranes were difficult. Intrapleural
fibrinolytics will degrade the fibrin membranes and facilitate drainage of
the pleural fluid in theory. But  most important study on the use of
intrapleural fibrinolytics for the treatment of complicated parapneumonic
effusion, even in subgroup analysis the administration of streptokinase
was not beneficial.80 In this multicenter, randomized, controlled, double-
blind study, 454 patients were randomized to receive 250,000 IU
streptokinase or saline at a total volume of 30 mL twice a day. There was
no difference in mortality, the need for surgical intervention, or the length
of hospitalization. At the present fibrinolytics are not recommended for
routine use. Tissue plasminogen activator (t-PA) is an alternative
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fibrinolytic agent.81 A study in rabbits demonstrated that the combination
of t-PA and recombinant DNase drained empyema fluid better than either
agent alone.82
Thoracoscopy
If tube thoracostomy fails, thoracoscopy  a more invasive
thoracoscopic procedure is needed, the fibrin membranes making the
loculations are broken down and removed, the peel covering the visceral
pleural can sometimes be removed with thoracoscopy and, at the end  a
chest tube is inserted.83  A chest CT will provide anatomic information
about the size and the extent of the empyema cavity hence need prior to
thoracoscopy.
A thickened visceral pleural peel without septations suggests that
the empyema may be chronic and probably will not be compliant to
thoracoscopic debridement alone.
Decortication
After tube thoracostomy and thoracoscopy fails this is the
procedure of choice. A full thoracotomy is performed to remove all
fibrous tissue and pus from the pleural space. The decortication is easier
to perform with thoracotomy and hence offers advantage over
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thoracoscopy . Pleural sepsis eliminated by decortication  and it allows
the underlying lung to expand. Decortication should not be performed for
removing thickened pleura, as it resolves spontaneously over several
months. Persistance of pleural thickening after 6 months, with reduction
in pulmonary function sufficiently to limit the patient's activities,
decortication should be option.
Open Drainage (Eloesser Flap)
Under local anesthesia, a skin flap overlying the lower part of the
empyema collection is made with a U-shaped incision,  to open the
empyema  cavity  the  ed  rib  segments  and   parietal  pleura  are  excised;  a
semipermanent opening is made by suturing  the skin flap inside the
cavity into which one or more large-bore short tubes are inserted. This
procedure allows complete drainage and frees the patient from attachment
to chest-tube bottles.83  The cavity should be irrigated daily with a mild
antiseptic solution  after the procedure, and a colostomy bag placed over
the  tubes  can  be  used  to  collect  the  drainage  from  the  tubes  .  In  those
patients who are too ill to tolerate the more extensive procedure Open
drainage is preferred to decortications and can be used for a prolonged
period. The median time for healing was over 120 days for drainage in
one study of 53 patients treated by an open-drainage procedure.84
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Bronchopleural Fistula Complicating Empyema
Adequate pleural drainage is crucial when an empyema is
complicated by   a  bronchopleural  fistula,  If  no drainage exteriorly with
chest tubes it  is likely to drain interiorly throughout the tracheobronchial
tree, producing a severe diffuse pneumonia. Whenever the chest
radiograph reveals an air-fluid level or the patient expectorates copious
quantities of sputum while lying on one side (by gravity dependent
drainage of the empyema into the bronchial tree) and not while lying on
the other side a  bronchopleural fistula should be suspected.
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MATERIALS  AND METHODS
The study is prospective analysis of patients cohort admitted to the
tertiary care  institute from the period of July 2009 to July 2010.
INCLUSION CRITERIA
(1)  All patients with parapneumonic effusion admitted to the
institute above age of fifteen years.
(2) All patients diagnosed to have  simple parapneumonic effusion
(3) All  Complicated parapneumonic effusion
(4) All Complex parapneumonic effusion.
EXCLUSION CRITERIA
(1)  All patients with effusion of other causes like trauma,
iatrogenic causes,were excluded.
(2)  Paediatric parapneumonic effusion excluded.
(3) Tuberculous pleural effusion excluded.
Definitions
1. Parapneumonic effusion
Any pleural effusion associated with bacterial pneumonia, lung
abscess, or bronchiectasis is a parapneumonic effusion 27.
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2. Empyema: An empyema, by definition, is pus in the pleural space
Empyema as pleural fluid with a specific gravity greater than
1.018, a WBC count greater than 500 cells/mm3, or a protein level greater
than 2.5 g/dL- weese29. Vianna 30 defined an empyema as pleural fluid on
which the bacterial cultures are positive or the WBC is greater than
15,000/mm3 and the protein level is above 3.0 g/dL.
The term empyema - Pleural effusions with thick, purulent
appearing pleural fluid.
Successful closed-tube drainage of a complicated parapneumonic
effusion is associated with improvement in the clinical and radiologic
status of the patient within 24 to 48 hours.
OUTCOME  DEFINITION
Success : In complicated parapneumonic effusion it is defined as
absolute drainage of  the effusion or improvement in sepsis syndrome
(fever & leucocytosis) after 2 weeks of appropriate antibiotics in
accordance with culture and sensitivity.
Failure:  Defined as incomplete drainage with failure of  resolution
of septic symptoms (fever, leucocytosis) or a fatal outcome.
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Patients characteristics studied
Patients characteristics such as
(1) Age
(2) Sex
(3) Co-morbid illness like diabetes mellitus, alcoholic
liver diseases
(4) Blood glucose
(5) Pleural fluid biochemical parameters such as PH ,
glucose, Culture & staining characteristics, leukocyte
count.
(6) Symptoms such as fever
(7) Other characteristics such as fibrin peel on
thoracoscopy  imaging evidence of loculation, serum
protein(albumin) , total wbc count were taken up for
analysis.
Factors Suggesting That a More Invasive Approach Will Be
Necessary for the Resolution of a Parapneumonic Effusion*
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1. Pus is present in the pleural space.
2. Positive pleural fluid Gram stain.
3. Pleural fluid glucose < 60 mg/dL.
4. Pleural fluid pH < 7.20.
5. Positive pleural fluid culture.
6. Pleural fluid lactate dehydrogenase > three times upper normal
limit for serum.
7. Loculated pleural fluid.
Chest tube were inserted fulfilling the above criteria by surgeon
pulmonary physician. The size used were  28F, 32F.
PH was measured using blood gas analyzer.
Hypoalbuminemia first appearing after 2 weeks of  antibiotic  was
considered for analysis.
Statistical analysis
Bacteriology of the pleural infection defined and determinants
(clinical, laboratory, & physical) of outcome in pleural space infection
especially complicated & complex parapneumonic effusion  were
determined .  Outcome were defined as success and failure.
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Univariate analysis of the variables done
Comparison of means by independent student t test & chi-square
test was done.
For dichotomous dependent variable confounding factors removed
independent predictors determined using Logistic regression analysis
especially binary logistic regression forward wald & backward
conditional regression.
SPSS version 17 software was used to compute the results.
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RESULTS
TABLES  No -1
AGE
Outcome Sex Mean N Std. Deviation
Male 47.1364 66 8.71583
Female 46.1538 13 7.28979
Failure
Total 46.9747 79 8.46255
Male 47.1250 40 10.98994
Female 48.3750 16 7.63217
success
Total 47.4821 56 10.09229
Male 47.1321 106 9.58578
Female 47.3793 29 7.43262
Total
Total 47.1852 135 9.14084
Cross table depicting mean age of male and female patients in
success and failed outcome in various form of parapneumonic effusion
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Tab-2 Crosstable  depicting  mean hydrogen ion concentration(PH) of
male and female patients in success and failed outcome in various
form of parapneumonic effusion
Hion
outcome Sex Mean N Std. Deviation
Male 5.679 66 1.3597
Female 6.162 13 .9921
Failure
Total 5.758 79 1.3132
Male 7.495 40 .8171
Female 7.750 16 1.0360
Success
Total 7.568 56 .8830
Male 6.364 106 1.4748
Female 7.038 29 1.2819
Total
Total 6.509 135 1.4576
GRAPHS
leucocyte
count<8000 leucocyte
count>10000
success
failure
0
20
40
60
80
Ca
se
s
success 49 7
failure 7 72
leucocyte count<8000 leucocyte count>10000
Graph  depicting cross tabulation of success and failure
with respesct to leucocyte count
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Tab-3Cross table depicting mean white blood cell count in pleural
fluid  of male and female patients in success and failed outcome in
various form of parapneumonic effusion
WBC
Outcome Sex Mean N Std. Deviation
Male 12268.03 66 2857.609
Female 9923.62 13 3886.823
Failure
Total 11882.24 79 3145.546
Male 6706.55 40 2550.524
Female 5655.56 16 1178.466
success
Total 6406.27 56 2284.960
Male 10169.36 106 3848.093
Female 7568.83 29 3447.438
Total
Total 9610.73 135 3903.296
0% 50% 100%
albumin<3
albumin>3
Failure 79 0
success 3 53
albumin<3 albumin>3
Graph  depicting cross tabulation of success and failure
with respesct to  Serum albumin
48
Tab -4 Cross table depicting mean serum albumin (after a week of
management) of male and female patients in success and failure in
various form of parapneumonic effusion
Serumprotein
Outcome Sex Mean N Std. Deviation
Male 2.2364 66 .35110
Female 2.4385 13 .45559
Failure
Total 2.2696 79 .37463
Male 3.4025 40 .46271
Female 3.5375 16 .38794
Success
Total 3.4411 56 .44345
Male 2.6764 106 .69166
Female 3.0448 29 .69209
Total
Total 2.7556 135 .70570
Albuminafterweek * outcome * sex Crosstabulation
Count
OutcomeSex
Failure Success
Total
albumin<3 66 3 69Albuminafterweek
albumin>3 0 37 37
Male
Total 66 40 106
albumin<3 13 0 13Albuminafterweek
albumin>3 0 16 16
Female
Total 13 16 29
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Tab-5  Death and outcome
Death * outcome Crosstabulation
Count
Outcome
Failure Success
Total
Alive 39 55 94
Death 40 1 41
Total 79 56 135
50
Table -6 fever in success and failure and their test of significance
Fever
Observed N Expected N Residual
No fever 50 67.5 -17.5
Present 85 67.5 17.5
Total 135
Outcome
Observed N Expected N Residual
Failure 79 67.5 11.5
Success 56 67.5 -11.5
Total 135
Test Statistics
Fever Outcome
Chi-Square 9.074a 3.919a
Df 1 1
Asymp. Sig. .003 .048
a. 0 cells (.0%) have expected frequencies less than 5. The minimum
expected cell frequency is 67.5.
PH<7
PH>7
success
failure
0
20
40
60
80
Ca
se
s
success 4 52
failure 64 15
PH<7 PH>7
Graph depicting cross tabulation of success and failure
with respesct to PH
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Results: Tab-7 univariate  logistic regression analysis of PH
Variables in the Equation
B(odd’s) S.E. Wald Df Sig. Exp(B)
PH(1) -4.016 .593 45.876 1 .000 .018Step 1a
Constant 1.243 .293 17.993 1 .000 3.467
a. Variable(s) entered on step 1: PH.
Table  of univariate analysis  depicting PH  with P value of 0.00 and
odd ‘s of failure with low pH as 4.016.
Categorical Variables Codings
Parameter
coding
Frequency
(1)
ph<7 68 1.000Ph  after  1  week  of
management ph>7 67 .000
stain/cul pos
stain/cul neg
success
failure
0
20
40
60
80
ca
se
s
success 34 22
failure 61 18
stain/cul pos stain/cul neg
Graph  depicting cross tabulation of success and failure
with respesct to stain and culture positivity
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Table (8) of univariate analysis  depicting culture and staining
positivity  with P value of 0.40 and odd ‘s of failure with low pH as
0.785.
Classification Tablea,b
Predicted
Outcome
Observed
Failure Success
Percentage
Correct
Failure 79 0 100.0outcome
Success 56 0 .0
Step 0
Overall Percentage 58.5
a. Constant is included in the model.
b. The cut value is .500
Variables in the Equation
B S.E. Wald Df Sig. Exp(B)
cultureposstain
(1)
.785 .383 4.199 1 .040 2.193Step 1a
Constant -.585 .214 7.459 1 .006 .557
a. Variable(s) entered on step 1: cultureposstain.
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Table(9)  of univariate analysis  depicting pleural fluid WBC count
with P value of 0.00 and odd ‘s of failure with low pH as 4.277.
Categorical Variables Codings
Parameter
coding
Frequency
(1)
count<8000 56 1.000leucocount after 1 week
count>10000 79 .000
Variables in the Equation
B S.E. Wald Df Sig. Exp(B)
Leukocyte(1) 4.277 .566 57.154 1 .000 72.000Step 1a
Constant -2.331 .396 34.657 1 .000 .097
a. Variable(s) entered on step 1: leukocyte.
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Table (10) of univariate analysis  depicting serum protein  with P
value of 0.00 and odd ‘s of failure with low protein as 7.412
Variables in the Equation
B S.E. Wald Df Sig. Exp(B)
serumprotein 7.412 1.525 23.640 1 .000 1656.473Step
1a Constant -21.310 4.356 23.929 1 .000 .000
a. Variable(s) entered on step 1: serumprotein.
Classification Tablea,b
Predicted
Outcome
Observed
Failure Success
Percentage
Correct
Failure 79 0 100.0outcome
Success 56 0 .0
Step 0
Overall Percentage 58.5
a. Constant is included in the model.
b. The cut value is .500
020
40
60
80
Ca
se
s
success 10 49
failure 61 18
present absent
Graph  depicting cross tabulation of success and failure
with respesct to Presence and absence of loculation
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Table (11) of univariate analysis  depicting loculation  with P value of
0.00 and odd ‘s of failure with low pH as 3.166.
Variables in the Equation
B S.E. Wald Df Sig. Exp(B)
loculation(1) 3.166 .485 42.626 1 .000 23.722Step
1a
Constant -2.165 .399 29.432 1 .000 .115
a. Variable(s) entered on step 1: loculation.
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Table (12) of univariate analysis  depictingfever  with P value of 0.09
and odd ‘s of failure with persistant fever as 4.016.
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Fever(1) .952 .367 6.742 1 .009 2.591Step
1a
Constant -.711 .231 9.488 1 .002 .491
a. Variable(s) entered on step 1: fever.
Categorical Variables Codings
Parameter codingFrequency
(1)
No fever 50 1.000Fever
present 85 .000
albumin
59%
41%
albumin<3
albumin>3
Graph depicting the percentage of patients with albumin<3 and
albumin>3 grams after treatment of complicated, complex
parapneumonic and simple parapneumonic effusion
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Table (13) Depicting  different variables and their univariate logistic
regression analysis.
Univariate  logistic regression analysis
Variable P value Odd’s S.E
PH 0.00 4.016 .593
WBC 0.00 4.277 .566
Loculation 0.00 3.166 .485
Fever 0.09 .711 .367
Serum proteins 0.00 7.412 1.525
Sex 0.095 0.708 0.424
Results show significant association with Ph, WBC, loculation,
fever, serum proteins. Their odd were
Ph-4.0                loculation-3.1                  fever-0.7
WBC-4.2                                                 serum albumin-7.4
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Table 14 multiple logistic regression analysis with analysis five
independent variables. Method = backward stepwise (conditional)
B S.E. Wald Df Sig. Exp(B)
PH(1) -5.610 2.573 4.753 1 .029 .004
leukocyte(1) 1.756 1.376 1.627 1 .202 5.787
loculation(1) 2.964 1.701 3.037 1 .081 19.377
cultureposstain(1) 1.038 1.612 .414 1 .520 2.824
Serumprotein 7.846 2.760 8.082 1 .004 2555.256
Step
1a
Constant -23.810 8.008 8.840 1 .003 .000
PH(1) -5.599 2.459 5.183 1 .023 .004
leukocyte(1) 1.674 1.401 1.427 1 .232 5.331
loculation(1) 3.330 1.712 3.785 1 .052 27.931
Serumprotein 7.907 2.835 7.780 1 .005 2715.493
Step
2a
Constant -23.840 8.198 8.457 1 .004 .000
PH(1) -6.137 2.590 5.615 1 .018 .002
loculation(1) 4.156 1.705 5.940 1 .015 63.785
Serumprotein 8.788 3.112 7.974 1 .005 6555.751
Step
3a
Constant -25.585 8.953 8.166 1 .004 .000
a. Variable(s) entered on step 1: PH, leukocyte, loculation, cultureposstain,
serumprotein.
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Table 15 : Logistic Regression
Block 1: Method = Forward Stepwise (Likelihood Ratio)
Variables in the Equation
B S.E. Wald Df Sig. Exp(B)
PH(1) -5.610 2.573 4.753 1 .029 .004
leukocyte(1) 1.756 1.376 1.627 1 .202 5.787
loculation(1) 2.964 1.701 3.037 1 .081 19.377
cultureposstain(1) 1.038 1.612 .414 1 .520 2.824
Serumprotein 7.846 2.760 8.082 1 .004 2555.256
Step 1a
Constant -23.810 8.008 8.840 1 .003 .000
PH(1) -5.599 2.459 5.183 1 .023 .004
leukocyte(1) 1.674 1.401 1.427 1 .232 5.331
loculation(1) 3.330 1.712 3.785 1 .052 27.931
Serumprotein 7.907 2.835 7.780 1 .005 2715.493
Step 2a
Constant -23.840 8.198 8.457 1 .004 .000
PH(1) -6.137 2.590 5.615 1 .018 .002
loculation(1) 4.156 1.705 5.940 1 .015 63.785
Serumprotein 8.788 3.112 7.974 1 .005 6555.751
Step 3a
Constant -25.585 8.953 8.166 1 .004 .000
a. Variable(s) entered on step 1: PH, leukocyte, loculation, cultureposstain,
serumprotein.
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INTERPRETATIONS
One hundred and thirty five patients with parapneumonic effusion
were analysed during the study period .
Ten with parapneumonic effusion had successful recovery treated
with antibiotics according to culture and sensitivity pattern.
One hundred and thirty five patients with complicated and complex
parapneumonic under tube thoracostomy with successful outcome in fifty
six patients. Seventy nine patients with CPE  had failed outcome.
Mortality was forty one (all cause) and CPE mortality was  forty.
Mortality percentage was 30.37%.
Various causes of parapneumonic effusion in the study were
pneumonia-88, lung abscess-10, bronchietasis-16, unidentified
causes(probability of pneumonia)-17.
Graph   Staining Characteristics of Patients
0.00= no growth
                  1.00= gram negative
                  2.00= gram positive
                  3.00= mixed infection.
PSEUDOMONAS GROWN IN CULTURE
PHOTOGRAPH SHOWING STAPHYLOCOCCUS AUREUS
GROWN IN CULTURE IN BLOOD AGAR.
MIXED INFECTION WITH KLEBSIELLA AND PROTEUS
SPECIES GROWN
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Bacteriology of  pleural space infection
Species Stain N
.00 43Nogrowth
Total 43
1.00 11Klebsiella
Total 11
2.00 28
Streptococi Total 28
2.00 13
Staphylococci Total 13
1.00 10Pseudomonas
Total 10
3.00 11Mixed inf
Total 11
1.00 7Ecoli
Total 7
1.00 8Providentia
Total 8
1.00 4Acinetobacter
Total 4
.00 43
1.00 40
2.00 41
3.00 11
Total
Total 135
0.00= no growth                        2.00= gram positive
1.00= gram negative.                 3.00= mixed.
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Causes of parapneumonic effusion No of cases(N)
Pneumonia 88
Lung abscess 10
Bronchiectasis 16
Unidentified cause  (high probabilityof
pneumonia)
17
Of  the  92  cases  with  stain  &culture  positivity  in  CPE  -   gram
negative infection  occurred in forty cases, forty one cases of gram
positive infection occurred, eleven cases of mixed infection occurred,
forty three cases had no growth  but  twenty eight cases had positivity
with staining method  probably denoting  anaerobic infection.
Outcome of pleural space infection
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Patients
characteristics
Success (n=56) Failure (n=79)
P
value
Age 47.18±9.14 46.97±8.71 0.752
Sex (m/f) 40/16 66/13 0.00
Pleural fluid  PH 7.56±0.88 5.75±1.31 0.00
   Wbc count 6406.27±2284.96 11887.24±3145 0.00
    Protein 3.44±0.78 3.44±0.62 0.97
Serum albumin after
week of treatment 3.44±0.44 2.26±0.37 0.01
Patient characteristics with P-value ( tested by t-test).
Comparison of outcome in cases of complicated &complex
parapneumonic effusion
Mean age in success and failure were 47.18 ±9.14 & 46.97±8.4 and
P value 0.752.
Gender variation in success and failure was significant with P value
of 0.00.
In univariate analysis pleural fluid protein did not show significant
results with mean protein in success and failure to be 3.44±0.62
and 3.44± 0.78 respectively with P value of 0.97.
Mean H+ ion in success was 7.56±0.88 while in failure was
5.75±1.31 p value of 0.00.
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Persistant fever after one week of antibiotics also had significant P
value of 0.048
Serum protein especially albumin in success and failure were
3.44±0.78 and 2.26±0.37 respectively with P value of o.oo.
Other parameters such as co-morbid illness, fibrinpeel (paucity of
cases) ,blood glucose did not show any significant results.
.
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DISCUSSION
The success rate for conventional tube thoracostomy drainage is 32
to 71%.86
Success rate reported from other studies is comparable to that of
41% in our study.88–90 High  mortality  rates  from  empyema  have  been
reported, ranging from 1 to 61%.87,91–93  In the present study, the overall
mortality rate was 31% and 40 fatalities (30%) were directly related to
empyemas. The duration of the pleural infection, the characteristics of the
pleural fluid, the presence or absence of loculations the overall condition
of the patient are the four critical important factors to be considered in the
selection of a pleural drainage method. These four factors also influence
the tube thoracostomy drainage outcome according to the review of
Moran95.
LeMense et al, 96 no difference in procedure success rates or
hospital stay was observed between multiloculated and uniloculated
empyemas, parapneumonic and nonparapneumonic empyemas, and
culture proved and biochemically proved empyemas. Their success rate
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of tube thoracostomy drainage was only 11%, because all patients had
loculated pleural fluid at presentation.
In contrast, in one series of 26 patients who underwent
thoracoscopy for chronic empyema of at least 3 weeks duration, over 50
percent had no evidence of intrapleural scar tissue – being still at the
fibrinopurulent stage of their infection.97 Success rate of tube
thoracostomy without loculation in our study was around 86.7%.
Patients should be considered for surgery if they have ongoing
signs of sepsis in association with a persistent pleural collection despite
drainage and antibiotics. Failure of sepsis to resolve within 5-7 days98 is
suggested as an appropriate period following which a surgical opinion
should be sought. Discussion with a thoracic surgeon should be
considered in all cases failing to respond.
Prognosis in pleural infection
The long-term survival of patients with pleural infection is good if
prompt treatment is initiated. In a series of 85 patients followed for up to
4 years, the mortality was 14% and all deaths occurred within the first
400 days after drainage99.  Death was due to comorbid condition and not
directly due to sepsis from the empyema. No reliable clinical, radiological
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or pleural fluid characteristics accurately determine patients prognosis at
initial presentation. Hypoalbuminaemia, the presence of loculated fluid
and anaerobic infections have been related to adverse outcome in
previous studies100-101 although not in recent reports. Long-term sequelae
of pleural empyema may include residual pleural thickening (up to 13%
of patients).30 This is not usually associated with functional impairment
although, rarely, extensive incapacitating pleural fibrosis may develop
(fibrothorax).102 103 104 Surgical decortication may occasionally provide
symptomatic benefit for patients with a fibrothorax. Pleural calcification,
bronchopleural fistula formation and development of empyema
necessitans (disruption of the parietal pleura with spontaneous discharge
of  pleural  contents  evident  under  the  chest  wall)  are  other  rare
complications.
Early thoracotomy has the additional advantage that if
decortications is accomplished within 2 weeks of pleural infection, the
visceral pleural rind usually is easily extricated from the lung.30
Hence early referral of failing cases will benefit from surgery. The
determinants such as PH (falling even after a week of management),
loculation, serum albumin falling after a week of management can
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successfully predict the failing cases according to our study which have
proved statistically by using logistic regression model.
Limitation of study
Lack of anaerobic culture is the limitation of the study.
Summary of Results and Discussion
Table 7 to 12 shows univariate logistic regression analysis.
? Tab-7= Univariate analysis  depicting PH  with P value of 0.00 and
odd ‘s of failure with low pH as 4.016.
? Tab-8 = univariate analysis  depicting culture and staining
positivity  with P value of 0.40 and odd ‘s of failure with low pH as
0.785.
? Table 9=   univariate analysis  depicting pleural fluid WBC count
with P value of 0.00 and odd ‘s of failure with low pH as 4.277.
? Table 10 = univariate analysis  depicting serum protein  with  P
value of 0.00 and odd ‘s of failure with low protein as 7.412.
? Table (11) of univariate analysis  depicting loculation  with P value
of 0.00 and odd ‘s of failure with low pH as 3.166.
? Table (12) of univariate analysis  depicting fever  with P value of
0.09 and odd ‘s of failure with persistant fever as 4.016.
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Variables such as PH, loculation, positive culture, WBC count, serum
albumin, fever had significant results in univariate analysis.
Table 14 & 15
? Multivariate logistic regression analysis showed significant results
for PH , loculation, serum protein in both forward Likelihood ratio
and backward condition methods.
? PH - 0.018 p value with odd’s ratio of 6.14 , loculation – p value of
0.015 with odd’s ratio of  4.15, serum albumin after weeks of
antibiotic –P value of 0.004 with odd 8.78. in both the methods.
But multivariate analysis showed results for PH, loculation and serum
albumin.(recommendation).
Thus making them the most important predictor of outcome of tube
thoracostomy for CPE. It is recommended based upon this study that
pleural PH, loculation, serum albumin, be taken as markers determining
the prognosis of parapneumonic effusion with regards to outcome.
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CONCLUSION
To conclude determinants such PH, pleural loculation, serum
albumin can predict the outcome of pleural space infection especially in
complicated & complex parapneumonic effusion. Such predictors can
help to reduce the morbidity and mortality associated with complicated
parapneumonic effusion by identification of failing cases and early
referral for definite management.
The bacteriology of pleural space infection in our study is
comparable to the bacteriology of similar studies with gram positive and
gram negative organisms occurring equally in seventy percentage of
infection.
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PROFORMA
Name:
Age:                        Sex:                          C.D. No:
Symptoms:                                             Duration
Cough
Sputum
Breathlessness
Fever
Chest pain:
Past history:
? H/O
? Diabetes.
? Alcoholic liver disease
? Chronic lung diseases
? Hypertension
? IHD
Previous admission for effusion/empyema
INVESTIGATIONS
1.Pleural fluid biochemistry
a. protein
           b. sugar
           c.PH
 cytology – WBC count.
2.Complete blood count:
3. Blood glucose:
4.Liver function test:
    a.SGOT          d. Serum protein (albumin/globulin).
    b. SGPT
    c SALP
5.    Sputum culture and sensitivity.
6.   Ultrasonogram of chest.
7.    CT SCAN
8. Thoracoscopy.
 Antibiotics
KEY WORDS TO   MASTER CHART
Hion- PH in continous variable.
                      Stain cul pos- Both positive for staining and culture growth.
                      Fibrin peel- appearance of fibrin peel in thoracoscopy.
BC- total pleural fluid leucocyte count.
Serum protein – Albumin in continuous variable.
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
1. 48 2 60.0 7.2 1.00 3.20 0 7,250 0 1 0 0 1 0 90.00 1 1 1.00 4.00
2. 49 1 50.0 5.8 0.00 3.10 1 11,920 0 1 1 1 1 1 146.00 2 0 0.00 2.20
3. 52 1 55.0 6.8 0.00 3.90 1 10,480 1 1 1 1 1 0 75.00 1 0 0.00 2.00
4. 39 1 90.0 8.2 1.00 3.70 0 7,500 0 1 0 0 1 0 100.00 1 1 1.00 3.30
5. 44 2 75.0 4.8 0.00 4.30 1 12,160 0 1 1 0 1 0 112.00 1 0 0.00 2.70
6. 63 1 60.0 7.6 1.00 3.00 0 7,000 0 1 0 0 1 0 176.00 2 0 0.00 2.40
7. 51 2 59.0 5.2 0.00 3.60 0 7,250 0 0 0 0 0 0 102.00 1 1 1.00 3.30
8. 29 1 85.0 8.9 1.00 3.60 0 6,750 0 0 0 0 0 0 106.00 1 1 1.00 3.50
9. 49 1 45.0 7.2 1.00 2.90 1 10,240 1 1 1 1 1 0 69.00 1 0 0.00 2.20
10. 35 1 40.0 6.0 0.00 2.50 1 12,400 1 0 0 0 1 0 79.00 1 0 0.00 2.30
11. 31 1 40.0 4.0 0.00 2.80 1 13,540 0 1 1 0 0 0 82.00 1 0 0.00 2.00
12. 42 1 80.0 5.0 0.00 3.10 1 10,000 0 0 1 0 1 0 95.00 1 0 0.00 2.00
13. 47 2 38.0 5.8 0.00 4.10 1 10,600 1 0 0 0 1 1 55.00 1 0 0.00 1.90
14. 55 1 60.0 7.0 1.00 3.20 1 10,100 0 0 0 0 0 0 73.00 1 1 0.00 3.30
15. 57 1 82.0 6.0 0.00 3.40 0 5,600 0 1 0 0 0 0 90.00 1 1 1.00 4.00
16. 52 1 43.0 7.0 1.00 5.60 1 10,100 0 1 1 0 1 0 160.00 2 0 0.00 2.00
17. 29 1 73.0 6.0 0.00 3.20 1 10,450 0 0 0 0 1 0 75.00 1 1 1.00 4.00
18. 64 1 72.0 7.4 1.00 4.20 1 11,320 0 1 0 0 0 0 77.00 1 1 1.00 3.00
19. 30 1 66.0 5.0 0.00 3.80 1 13,200 1 0 1 0 1 0 69.00 1 0 0.00 1.60
20. 44 1 39.0 6.0 0.00 3.80 1 10,200 0 1 1 0 1 0 49.00 1 0 0.00 2.10
21. 49 1 48.0 7.6 1.00 3.80 1 13,200 0 1 0 0 1 0 55.00 1 1 1.00 3.00
22. 50 2 66.0 8.2 1.00 3.60 1 11,200 0 1 1 0 0 0 68.00 1 0 0.00 2.60
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
23. 43 2 55.0 8.7 1.00 3.80 0 4,900 0 1 0 0 0 0 65.00 1 1 1.00 4.00
24. 56 1 50.0 8.5 1.00 3.50 1 14,000 1 1 1 0 0 0 62.00 1 0 0.00 1.60
25. 48 1 39.0 8.4 1.00 3.90 1 13,800 0 1 1 0 0 0 59.00 1 0 0.00 2.60
26. 47 1 57.0 8.2 1.00 4.00 0 7,120 0 0 0 0 0 0 70.00 1 1 0.00 2.50
27. 43 1 55.0 5.4 0.00 2.60 1 12,800 1 1 0 0 1 0 56.00 1 0 0.00 2.30
28. 56 2 56.0 7.7 1.00 3.44 0 5,600 0 0 0 0 1 0 67.00 1 1 1.00 3.00
29. 52 1 65.0 9.1 1.00 3.90 1 11,200 0 1 1 0 1 0 171.00 2 0 0.00 2.20
30. 42 1 36.0 7.9 1.00 2.80 1 10,300 0 0 0 0 0 1 140.00 2 0 0.00 2.40
31. 47 2 48.0 7.2 1.00 3.10 0 6,700 0 1 0 0 1 0 52.00 1 1 1.00 3.70
32. 39 1 69.0 6.0 0.00 4.00 1 13,000 0 1 1 0 0 0 70.00 1 0 0.00 2.00
33. 41 1 46.0 7.0 1.00 3.10 0 5,900 0 0 1 0 0 0 62.00 1 1 1.00 3.60
34. 62 1 34.0 6.0 0.00 4.00 1 11,000 0 0 1 1 1 0 48.00 1 0 0.00 2.10
35. 53 1 80.0 5.8 0.00 6.40 1 17,800 1 1 1 1 1 1 180.00 2 0 0.00 1.50
36. 37 1 58.0 8.0 1.00 7.90 0 4,300 0 0 0 0 1 0 90.00 1 1 1.00 3.90
37. 46 1 56.0 5.6 0.00 3.40 1 15,300 0 1 1 0 1 0 61.00 1 0 0.00 2.00
38. 28 1 54.0 7.0 1.00 2.90 0 4,900 0 0 0 0 0 0 60.00 1 1 1.00 4.00
39. 29 1 45.0 6.6 0.00 3.10 1 10,800 1 1 1 0 1 1 50.00 1 0 0.00 2.10
40. 61 2 67.0 5.3 0.00 3.20 1 13,100 0 0 0 0 1 0 69.00 1 0 0.00 2.20
41. 51 1 51.0 4.1 0.00 3.50 1 11,500 0 0 1 1 1 0 55.00 1 0 0.00 2.90
42. 39 1 49.0 7.3 1.00 3.70 0 3,470 0 1 0 0 1 0 80.00 1 1 1.00 3.00
43. 41 1 51.0 4.7 0.00 4.10 1 17,900 0 1 1 1 1 1 80.00 1 0 0.00 2.70
44. 37 2 55.0 7.1 1.00 2.90 0 3,248 1 0 1 0 1 0 78.00 1 0 0.00 2.10
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
45. 56 1 57.0 9.0 1.00 4.10 0 4,321 0 0 0 0 0 0 59.00 1 1 1.00 3.60
46. 50 1 32.0 3.8 0.00 4.10 1 10,700 0 1 1 0 0 0 50.00 1 0 0.00 2.60
47. 56 1 38.0 4.0 0.00 3.10 1 12,450 1 1 1 1 1 1 149.00 2 0 0.00 2.30
48. 42 2 42.0 7.0 1.00 3.40 0 2,489 0 1 0 0 1 0 61.00 1 1 1.00 3.60
49. 48 2 51.0 6.0 0.00 3.60 1 10,060 0 1 1 0 0 0 53.00 1 0 0.00 2.70
50. 49 1 51.0 3.7 0.00 3.80 1 12,600 1 0 0 0 1 0 51.00 1 0 0.00 2.20
51. 27 1 44.0 7.0 1.00 3.70 1 12,500 0 1 1 0 1 0 61.00 1 1 1.00 3.00
52. 28 1 45.0 6.3 0.00 2.70 1 10,210 1 1 0 0 0 0 151.00 2 0 0.00 2.60
53. 51 2 56.0 7.0 1.00 3.00 0 6,570 0 0 0 3 1 0 158.00 2 1 1.00 3.00
54. 39 2 72.0 8.4 1.00 3.90 0 5,700 0 1 0 3 1 0 167.00 2 1 1.00 4.00
55. 41 1 54.0 8.9 1.00 3.00 0 4,900 0 0 1 0 0 0 70.00 1 1 1.00 4.10
56. 49 1 72.0 5.6 0.00 4.30 1 17,400 0 1 1 1 1 0 74.00 1 0 0.00 2.10
57. 39 2 70.0 7.0 1.00 3.10 0 3,400 0 1 1 0 0 0 88.00 1 0 0.00 2.80
58. 55 1 56.0 6.4 0.00 4.00 1 10,100 1 0 1 0 1 0 71.00 1 0 0.00 1.50
59. 33 1 38.0 5.6 0.00 3.60 1 14,300 0 1 1 0 1 0 59.00 1 0 0.00 2.00
60. 33 1 39.0 7.0 1.00 3.20 0 8,000 0 0 1 0 0 0 57.00 1 1 1.00 4.00
61. 52 1 40.0 6.0 0.00 3.00 0 6,000 0 1 0 0 0 0 71.00 1 1 1.00 3.50
62. 56 1 44.0 7.0 1.00 3.00 1 10,200 1 0 0 0 1 0 57.00 1 0 0.00 2.20
63. 67 2 54.0 9.1 1.00 3.20 0 4,500 1 1 0 0 0 0 60.00 1 1 1.00 3.80
64. 48 1 49.0 4.8 0.00 3.50 1 12,000 0 0 0 0 0 0 49.00 1 0 0.00 2.10
65. 61 1 52.0 4.4 0.00 3.20 1 12,400 1 1 1 0 0 0 53.00 1 0 0.00 2.00
66. 50 1 39.0 3.3 0.00 2.90 1 12,000 1 0 0 0 1 0 50.00 1 0 0.00 1.90
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
67. 46 1 49.0 3.2 0.00 3.40 1 10,900 0 1 1 0 0 0 50.00 1 0 0.00 2.50
68. 40 1 50.0 5.8 0.00 4.00 0 6,900 0 1 0 0 1 0 54.00 1 0 0.00 2.80
69. 46 2 43.0 8.0 1.00 4.20 0 5,400 0 1 1 0 1 0 57.00 1 1 1.00 3.50
70. 70 1 36.0 6.2 0.00 3.10 1 13,800 0 1 1 0 1 0 41.00 1 0 0.00 2.70
71. 55 1 36.0 5.9 0.00 3.40 0 1,330 1 1 0 0 1 0 40.00 1 0 0.00 2.60
72. 46 1 36.0 5.8 0.00 3.20 1 13,000 0 1 1 0 0 0 46.00 1 0 0.00 2.50
73. 48 1 46.0 6.7 0.00 4.10 1 14,000 0 0 0 0 1 0 48.00 1 0 0.00 2.70
74. 45 1 48.0 7.0 1.00 4.20 0 7,000 0 1 0 0 0 0 49.00 1 1 1.00 3.00
75. 43 1 48.0 8.0 1.00 4.50 0 4,800 0 1 0 0 1 0 56.00 1 1 1.00 3.20
76. 46 1 43.0 8.0 1.00 4.20 0 5,400 1 1 0 0 0 0 49.00 1 0 0.00 2.50
77. 50 1 52.0 5.6 0.00 3.60 1 12,000 0 1 1 0 0 0 80.00 0 0 0.00 2.30
78. 51 1 50.0 5.6 0.00 4.10 1 13,000 0 1 0 0 1 0 79.00 1 0 0.00 2.10
79. 61 1 54.0 7.0 1.00 2.90 0 7,010 0 1 0 0 1 0 78.00 1 1 1.00 3.60
80. 37 1 67.0 6.2 0.00 2.90 1 10,410 1 0 1 0 0 0 102.00 1 0 0.00 2.10
81. 43 1 52.0 8.9 1.00 3.10 0 7,300 0 0 0 0 0 0 100.00 1 1 1.00 3.30
82. 39 2 61.0 9.8 1.00 3.10 0 6,200 0 0 1 0 0 0 101.00 1 1 1.00 3.00
83. 41 1 49.0 4.3 0.00 3.30 1 11,000 1 1 1 1 1 1 58.00 1 0 0.00 2.20
84. 62 1 52.0 7.4 1.00 3.80 0 5,300 0 0 0 0 1 0 140.00 2 1 1.00 3.00
85. 48 1 49.0 6.0 0.00 3.50 1 12,000 0 0 0 0 0 0 61.00 1 0 0.00 2.10
86. 38 1 51.0 7.0 1.00 3.20 1 11,200 0 1 0 0 0 0 60.00 1 1 1.00 3.40
87. 51 1 36.0 4.8 0.00 3.10 1 18,020 1 1 1 1 1 1 58.00 1 0 0.00 2.10
88. 57 1 56.0 8.1 1.00 4.00 0 8,000 0 1 0 0 0 0 57.00 1 1 1.00 3.30
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
89. 40 1 41.0 5.6 0.00 3.20 1 15,400 1 1 1 0 0 0 55.00 1 0 0.00 1.50
90. 46 1 50.0 5.2 0.00 3.20 1 13,200 1 1 1 0 0 0 169.00 2 0 0.00 2.10
91. 28 1 55.0 4.0 0.00 3.00 1 11,800 1 1 1 1 1 0 102.00 1 0 0.00 2.00
92. 39 1 57.0 4.6 0.00 3.00 1 14,200 1 1 1 0 1 0 110.00 1 0 0.00 2.00
93. 41 1 54.0 4.8 0.00 3.00 1 12,600 1 1 1 0 1 0 102.00 1 0 0.00 1.90
94. 42 2 39.0 5.0 0.00 3.70 1 10,200 0 0 0 0 1 0 100.00 1 0 0.00 1.70
95. 50 1 51.0 3.9 0.00 4.00 1 10,300 1 1 1 1 1 1 109.00 1 0 0.00 1.90
96. 29 1 68.0 9.0 1.00 3.00 0 4,521 0 1 0 0 0 0 108.00 1 1 0.00 3.70
97. 55 1 59.0 7.0 1.00 3.80 0 3,600 0 0 0 0 1 0 100.00 1 1 1.00 3.30
98. 53 1 67.0 6.9 0.00 2.70 1 14,700 1 1 1 0 1 0 97.00 1 0 0.00 2.70
99. 53 1 56.0 7.0 1.00 3.00 0 5,400 0 0 0 0 1 0 91.00 1 1 1.00 3.80
100. 40 2 63.0 6.0 0.00 3.10 1 10,900 1 1 1 0 1 0 79.00 1 0 0.00 3.40
101. 57 1 56.0 7.0 1.00 3.00 1 11,200 0 1 0 0 1 0 96.00 1 1 1.00 3.50
102. 45 1 64.0 5.0 0.00 3.10 1 11,200 1 1 1 0 1 0 89.00 1 0 0.00 2.20
103. 51 1 36.0 6.7 0.00 3.10 1 18,040 0 1 1 0 1 0 79.00 1 0 0.00 2.60
104. 57 1 56.0 6.5 0.00 3.60 1 14,200 1 1 1 0 1 0 89.00 1 0 0.00 2.50
105. 49 1 63.0 7.0 1.00 3.80 0 4,520 0 1 0 0 1 0 88.00 1 1 1.00 3.00
106. 47 1 39.0 6.5 0.00 3.40 1 11,000 1 1 1 0 1 0 81.00 1 0 0.00 2.10
107. 50 2 60.0 6.4 0.00 2.90 1 10,900 0 1 1 0 1 0 89.00 1 0 0.00 2.60
108. 39 1 63.0 6.2 0.00 3.20 1 10,700 1 1 1 0 1 0 79.00 1 0 0.00 1.60
109. 61 1 63.0 7.0 1.00 3.00 0 6,400 0 1 0 0 1 0 104.00 1 1 1.00 2.00
110. 58 1 67.0 7.2 1.00 3.20 0 4,800 0 1 0 0 1 0 99.00 1 1 1.00 3.70
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
111. 42 1 62.0 4.2 0.00 3.00 1 10,700 1 1 1 0 1 0 71.00 1 0 0.00 2.40
112. 47 1 53.0 7.8 1.00 3.00 0 6,300 0 0 0 0 1 0 120.00 1 1 1.00 3.00
113. 49 1 86.0 4.8 0.00 3.00 1 12,400 1 1 1 0 1 0 134.00 1 0 0.00 2.80
114. 54 1 58.0 7.0 1.00 3.70 0 4,000 0 0 0 0 1 0 108.00 1 1 1.00 3.00
115. 55 1 66.0 6.4 0.00 3.00 1 12,000 0 1 1 0 0 0 101.00 1 0 0.00 2.70
116. 49 1 77.0 7.2 1.00 3.00 1 13,900 1 1 1 0 1 0 100.00 1 0 0.00 2.70
117. 47 1 58.0 7.4 1.00 3.10 0 3,800 0 1 1 0 1 0 102.00 1 1 1.00 3.00
118. 54 1 59.0 7.5 1.00 3.00 0 5,300 0 0 0 0 0 0 98.00 1 1 1.00 3.10
119. 50 1 69.0 5.6 0.00 2.90 1 15,700 1 1 1 0 1 0 79.00 1 0 0.00 2.70
120. 51 1 55.0 7.0 1.00 3.60 1 15,900 1 1 1 0 1 0 61.00 1 0 0.00 2.80
121. 49 2 67.0 6.4 0.00 3.20 1 16,300 1 1 1 0 1 0 79.00 1 0 0.00 2.20
122. 56 2 43.0 5.1 0.00 3.00 1 12,349 0 1 1 0 1 0 56.00 1 0 0.00 2.70
123. 37 2 59.0 7.0 1.00 3.80 0 4,590 0 1 1 0 0 0 102.00 1 0 0.00 2.10
124. 65 1 67.0 3.1 0.00 2.90 1 14,780 0 1 1 0 1 0 105.00 1 0 0.00 2.00
125. 41 1 37.0 3.1 0.00 4.10 1 12,370 0 1 1 0 1 0 106.00 1 0 0.00 2.50
126. 50 1 70.0 7.6 1.00 3.00 0 4,890 0 1 0 0 0 0 101.00 1 1 1.00 4.00
127. 53 2 71.0 7.5 1.00 4.10 0 5,600 0 1 0 0 1 0 89.00 1 1 1.00 4.00
128. 45 2 71.0 7.8 1.00 3.80 0 6,600 0 1 0 0 0 0 102.00 1 1 1.00 3.80
129. 29 1 67.0 7.0 1.00 2.90 0 7,000 0 0 0 0 1 0 98.00 1 1 1.00 4.00
130. 39 2 69.0 8.0 1.00 2.70 0 5,480 0 1 0 0 0 0 88.00 1 1 1.00 3.60
131. 60 1 78.0 8.3 1.00 1.90 0 5,380 0 1 0 0 0 0 79.00 1 1 1.00 3.30
132. 51 2 85.0 8.1 1.00 3.00 0 5,250 0 1 0 0 1 0 89.00 1 1 1.00 3.20
No. Age Sex PG Hion PH Protein LEU WBC MR Cul+ Locu Fibrin Fever Pus RBS DM OC Alb SP
133. 59 1 69.0 9.0 1.00 2.80 0 6,210 0 1 0 0 0 0 86.00 1 1 1.00 4.00
134. 57 2 73.0 7.3 1.00 2.80 0 5,000 0 1 0 0 0 0 120.00 1 1 1.00 3.10
135. 51 1 75.0 7.1 1.00 2.90 0 8,000 0 1 0 0 0 0 80.00 1 1 1.00 3.60
Key
Sex Mortality (MR) Culture Positive (Cul+) Loculation (Locu)
1 = Male 0 = Alive 1 = Growth 1 = Present
2 = Female 1 = Death 0 = No Growth 0 = Absent
PH Diabetes (DM) Outcome (OC) Albumin (Alb)
1 - > 7 1 = Absent 1 = Success 0 - < 3
0 - < 7 2 = Present 0 = Failure 1 - > 3
Leucocyte (LEU)
1 - > 10000
0 - < 8000
Sl.No. Positivestaincul Outcome Species Stain
1. staingrowth success klebsiella 1.00
2. staingrowth failure pseudomonas 1.00
3. staingrowth failure providentia 1.00
4. staingrowth success klebsiella 1.00
5. staingrowth failure pseudomonas 1.00
6. staingrowth failure acinetobacter 1.00
7. nogrowth success nogrowth 0.00
8. nogrowth success nogrowth 0.00
9. staingrowth failure streptococi 2.00
10. nogrowth failure nogrowth 0.00
11. staingrowth failure streptococi 2.00
12. nogrowth failure nogrowth 0.00
13. nogrowth success nogrowth 0.00
14. staingrowth success streptococi 2.00
15. nogrowth success nogrowth 0.00
16. staingrowth failure streptococi 2.00
17. nogrowth success nogrowth 0.00
18. staingrowth success staphylococci 2.00
19. nogrowth failure nogrowth 0.00
20. staingrowth failure klebsiella 1.00
21. staingrowth success klebsiella 1.00
22. staingrowth failure staphylococci 2.00
23. staingrowth failure streptococi 2.00
24. nogrowth failure nogrowth 0.00
25. staingrowth failure mixed inf 3.00
26. nogrowth success nogrowth 0.00
27. staingrowth failure ecoli 1.00
28. nogrowth success nogrowth 0.00
29. staingrowth failure providentia 1.00
Sl.No. Positivestaincul Outcome Species Stain
30. nogrowth failure nogrowth 0.00
31. staingrowth success ecoli 1.00
32. staingrowth failure staphylococci 2.00
33. nogrowth success nogrowth 0.00
34. nogrowth failure nogrowth 0.00
35. staingrowth failure streptococi 2.00
36. nogrowth success nogrowth 0.00
37. staingrowth failure streptococi 2.00
38. nogrowth success nogrowth 0.00
39. staingrowth failure staphylococci 2.00
40. nogrowth failure streptococi 2.00
41. nogrowth failure nogrowth 0.00
42. staingrowth success mixed inf 3.00
43. staingrowth failure providentia 1.00
44. nogrowth failure nogrowth 0.00
45. nogrowth success nogrowth 0.00
46. staingrowth failure acinetobacter 1.00
47. staingrowth failure ecoli 1.00
48. staingrowth success klebsiella 1.00
49. staingrowth failure pseudomonas 1.00
50. nogrowth failure nogrowth 0.00
51. staingrowth success mixed inf 3.00
52. staingrowth failure streptococi 2.00
53. nogrowth success nogrowth 0.00
54. staingrowth success streptococi 2.00
55. nogrowth success nogrowth 0.00
56. staingrowth failure staphylococci 2.00
57. staingrowth failure streptococi 2.00
58. nogrowth failure nogrowth 0.00
Sl.No. Positivestaincul Outcome Species Stain
59. staingrowth failure klebsiella 1.00
60. nogrowth success nogrowth 0.00
61. staingrowth success pseudomonas 1.00
62. nogrowth failure nogrowth 0.00
63. staingrowth success mixed inf 3.00
64. nogrowth failure nogrowth 0.00
65. staingrowth failure ecoli 1.00
66. nogrowth failure nogrowth 0.00
67. staingrowth failure providentia 1.00
68. staingrowth failure acinetobacter 1.00
69. staingrowth success providentia 1.00
70. staingrowth failure ecoli 1.00
71. staingrowth failure providentia 1.00
72. staingrowth failure streptococi 2.00
73. nogrowth failure nogrowth 0.00
74. staingrowth success staphylococci 2.00
75. staingrowth success klebsiella 1.00
76. staingrowth failure streptococi 2.00
77. staingrowth failure streptococi 2.00
78. staingrowth failure staphylococci 2.00
79. staingrowth success streptococi 2.00
80. nogrowth failure nogrowth 0.00
81. nogrowth success nogrowth 0.00
82. nogrowth success nogrowth 0.00
83. staingrowth failure pseudomonas 1.00
84. nogrowth success nogrowth 0.00
85. nogrowth failure nogrowth 0.00
86. staingrowth success streptococi 2.00
87. staingrowth failure klebsiella 1.00
Sl.No. Positivestaincul Outcome Species Stain
88. staingrowth success staphylococci 2.00
89. staingrowth failure streptococi 2.00
90. staingrowth failure providentia 1.00
91. nogrowth failure nogrowth 0.00
92. staingrowth failure mixed inf 3.00
93. staingrowth failure pseudomonas 1.00
94. nogrowth failure nogrowth 0.00
95. staingrowth failure mixed inf 3.00
96. staingrowth failure mixed inf 3.00
97. nogrowth success nogrowth 0.00
98. staingrowth failure streptococi 2.00
99. nogrowth success nogrowth 0.00
100.  staingrowth failure staphylococci 2.00
101.  staingrowth success streptococi 2.00
102.  staingrowth failure streptococi 2.00
103.  staingrowth failure klebsiella 1.00
104.  staingrowth failure pseudomonas 1.00
105.  nogrowth success nogrowth 0.00
106.  staingrowth failure streptococi 2.00
107.  staingrowth failure mixed inf 3.00
108.  staingrowth failure staphylococci 2.00
109.  staingrowth success providentia 1.00
110.  nogrowth success nogrowth 0.00
111.  staingrowth failure ecoli 1.00
112.  nogrowth success nogrowth 0.00
113.  staingrowth failure mixed inf 3.00
114.  nogrowth success nogrowth 0.00
115.  staingrowth failure pseudomonas 1.00
116.  staingrowth failure streptococi 2.00
Sl.No. Positivestaincul Outcome Species Stain
117.  staingrowth success staphylococci 2.00
118.  nogrowth success nogrowth 0.00
119.  staingrowth failure klebsiella 1.00
120.  staingrowth failure streptococi 2.00
121.  staingrowth failure mixed inf 3.00
122.  staingrowth failure streptococi 2.00
123.  staingrowth failure staphylococci 2.00
124.  staingrowth failure streptococi 2.00
125.  staingrowth failure pseudomonas 1.00
126.  staingrowth success streptococi 2.00
127.  staingrowth success staphylococci 2.00
128.  staingrowth success pseudomonas 1.00
129.  staingrowth success streptococi 2.00
130.  staingrowth success mixed inf 3.00
131.  staingrowth success pseudomonas 1.00
132.  staingrowth success streptococi 2.00
133.  staingrowth success klebsiella 1.00
134.  staingrowth success ecoli 1.00
135.  nogrowth success nogrowth 0.00
Key
0.0 =  No growth
1.0 =  gram positive
2.0 =  gram negative
3.0 = Mixed Growth
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VOLUNTERY & I MAY REFUSE TO PARTICIPATE AT ANY TIME
WITHOUT GIVING ANY REASON AND WITHOUT AFFECTING
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THORACOSTOMY WHICH IS PART OF MANAGEMENT TOOL
FOR MY DISEASE
         NAME OF THE PARTICIPANT:
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          INVESTIGATOR
ABSTRACT
Study objectives: To describe bacteriology of pleural space
infection and determine the factors that would predict the outcome of the
infection in various  classes of  parapneumonic effusion.
 Study design: Prospective review of patients admitted to the
tertiary respiratory care hospital from june 2009 to june 2011 with the
diagnosis of simple, complicated and complex parapneumonic effusion.
Materials and methods :  Patients features such as Age ,sex, pleural
fluid protein, WBC, PH , Glucose, pleural loculation, co-morbid illness
like diabetes, Pleural fluid positivity for gram stain and culture growth,
mortality, serum albumin levels after a week treatment, effusion quantity
were analysed to identify the determinants of outcome in Complicated
parapneumonic Effusion. To define the bacteriology of pleural space
infection pleural fluid gram staining and growth in culture were analysed.
The data were compared  between two outcomes success and failure and
statistically analysis using multiple logistic regression done .
Results: Of  the one hundred thirty five  diagnosis of simple
parapneumonic ten had complete resolution of symptoms. Out of the
reamaining ,one hundred twenty  five cases  of parapneumonic effusion .
Seventy nine had failed outcome and fifty six had successful outcome.
univariate and multivariate logistic regression used. Bacteriology of
pleural space infection showed both gram positive and gram negative
growth  comparable results to other studies.. Univariate analysis showed
PH, loculation , positive stain , culture, fever, serumalbumin to be
statistically significant. Multivariate analysis  showed PH, loculation,
serumalbumin were important  determinants predicting either success or
failure of tube thoracostomy.
Conclusion; By multivariate analysis pleural fluid PH,  loculation  ,
serum albumin were predictive factors for outcome of complicated and
complex parapneumonic effusion. They could be used for reffering the
cases for definitive management.
Key words: bacteriology , pleural infection, outcome .
